Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies
Cancer · 15.11.2026 · 132 (22)
DOI: 10.1002/cncr.70672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 13.11.2026. Verfasst von Cuipeng Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Ovarian Neoplasms, Autoantibodies, Cystadenocarcinoma, Serous. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Autoantibodies (AAbs) against p53 develop in a fraction of patients with ovarian cancer, but the mechanisms underlying their development remain unknown. High‐grade serous carcinoma (HGSC) is the most prevalent and lethal histotype, and nearly all HGSCs exhibit TP53 mutations, although only 20%–30% evoke anti‐p53 AAbs.
Methods
Serum and tissue samples were analyzed from 174 patients with ovarian cancer who were included in the Danish Pelvic Mass/Gynecologic Ovarian Vulva Endometrial and Cervix Cancer study.
Results
Elevated levels of immunoglobulin G anti‐p53 AAbs were detected in 30 patients, all with HGSC. Among the patients who had HGSC, elevated levels of anti‐p53 AAbs were identified in 17% of those with early stage (I–II) disease and in 23% of those with late stage (III + IV) disease. Ninety‐seven percent of samples with elevated anti‐p53 AAbs had TP53 mutations, 93% had mutations restricted to the DNA‐binding domain, and 89% had overexpression of p53 protein in tissue sections. Neither anti‐p53 AAb levels nor p53 protein expression was associated with survival. Infiltration of CD20‐positive/CD23‐positive B cells and CD8‐positive T cells correlated with anti‐p53 AAbs, consistent with heightened immune activation. Increased immunoglobulin production appeared to be specific for p53 in that no correlation was observed between anti‐p53 AAbs and human epididymis protein 4 antigen–AAb complexes. Absorption experiments have suggested that anti‐p53 AAbs associated with HGSC are directed against epitopes on wild‐type p53 protein. TP 53 mutation and overexpression of p53 appear to be necessary, but not sufficient, for the induction of anti‐p53 AAbs.
Conclusions
Anti‐p53 AAbs identify a distinct subset of TP53 ‐mutant HGSC with an active tumor immune microenvironment and warrant further development as a biomarker for early detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Gynecology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
- Biodesign Institute, Arizona State University, Tempe, Arizona, USA.
ORCID-Profile: Tim S Poulsen, Robert C Bast
Förderung
- NCI NIH HHS
Zitieren
APA
Qiu, C., Høgdall, C., Yang, H., Yang, W. L., Poulsen, T. S., Anderson, K. S., Lu, Z., Bast, R. C., & Høgdall, E. (2026). Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies. Cancer, 132(22). https://doi.org/10.1002/cncr.70672
Vancouver
Qiu C, Høgdall C, Yang H, Yang WL, Poulsen TS, Anderson KS, et al. Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies. Cancer. 2026;132(22). doi:10.1002/cncr.70672
BibTeX
@article{Qiu2026,
author = {Qiu, Cuipeng and Høgdall, Claus and Yang, Hailing and Yang, Wei-Lei and Poulsen, Tim S and Anderson, Karen S and Lu, Zhen and Bast, Robert C and Høgdall, Estrid},
title = {Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies},
journal = {Cancer},
year = {2026},
volume = {132},
number = {22},
doi = {10.1002/cncr.70672}
}
EUVIMED